Danielle Isen, DO
Neurology · Mobile, ALNPI 1982135273
Payments from drug & device makers
Across 99 payments — averaging $93.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Amgen$692
- UCB, Inc.$421
- Merz North America, Inc.$158
- Supernus Pharmaceuticals, Inc.$149
- Acorda Therapeutics, Inc$128
- plus $446 from 13 others
What the payments were for
- Speaking & faculty fees$5,58860%
- Travel & lodging$1,21613%
- Food & beverage$2,46927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $7,279 |
| Amgen(2 entities) | 22 | $692 |
| UCB, Inc. | 16 | $421 |
| Merz North America, Inc. | 1 | $158 |
| Supernus Pharmaceuticals, Inc. | 8 | $149 |
| Acorda Therapeutics, Inc | 8 | $128 |
| Eisai Inc. | 6 | $111 |
| AbbVie(2 entities) | 4 | $75 |
| Adamas Pharmaceuticals, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Rxsight Inc | 1 | $33 |
| EMD Serono, Inc. | 1 | $30 |
| SK Life Science, Inc. | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $22 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Zogenix Inc. | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,273 in reported general payments places this provider in the 60th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide ErPyridostigmine Bromide | 20 | $8,429 |
| Pyridostigmine Bromide | 86 | $7,560 |
| Acetazolamide ErAcetazolamide | 41 | $3,276 |
| Glycopyrrolate | 32 | $1,595 |
| Gabapentin | 33 | $360 |
| Prednisone | 58 | $294 |
| Omeprazole | 28 | $229 |
| Amitriptyline Hcl | 13 | $195 |
| Methylprednisolone | 15 | $139 |
| Sumatriptan Succinate | 11 | $125 |
| Topiramate | 12 | $110 |
| Nortriptyline Hcl | 15 | $96 |
Paid to pharmacies, not to this prescriber.
Other neurology in Mobile
- Daniel DeesMobile$894K
- Hayden LongMobile$386K
- William KilgoMobile$334K
- John HintonMobile$270K
- Charles MarkleMobile$212K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$164K
- Matthew McLeanMobile$113K
- Laura MintoMobile$92K
- Steve CordinaMobile$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.